Skip to main content

Table 3 Fold change of genes in LNCaP cells exposed to combination treatment or mono-treatment with Taxotere or Furtulon

From: Gene expression profiling revealed novel mechanism of action of Taxotere and Furtulon in prostate cancer cells

Gene Taxotere Furtulon Taxotere+Furtulon
  6 h 36 h 72 h 6 h 36 h 72 h 6 h 36 h 72 h
Cell cycle and apoptosis          
NM_001786.1 cell division cycle 2 (CDC2) -1.2 -7.5 -12.1 -1.1 -2.8 -1.6 NC -4.0 -14.9
D88357.1 mRNA for CDC2 delta T -1.1 -6.1 -14.9 NC -2.8 -1.6 -1.1 -4.3 -13.0
NM_001237.1 cyclin A2 (CCNA2) -1.2 -5.7 -12.1 NC NC -2.1 -1.1 -8.6 -13.9
NM_004702.1 cyclin E2 (CCNE2) 1.6 -5.3 -3.2 NC -2.3 -1.7 -1.7 -4.9 -8.0
AF112857.1 cyclin E2 splice variant 1 mRNA 1.2 -3.5 -3.2 NC -2.0 -1.6 -1.4 -7.0 -8.6
NM_001761.1 cyclin F (CCNF) -1.5 -2.5 -3.7 -1.1 -1.1 -2.0 -1.4 -2.3 -2.8
AB012305.1 cyclin-dependent kinase 2 -1.7 -3.5 -5.3 -2.0 -2.1 -2.1 NC -2.8 -3.5
U30872.1 mitosin mRNA -1.2 -4.6 -6.1 NC -2.1 -1.3 NC -3.2 -7.0
NM_000389.1 cyclin-dependent kinase inhibitor 1A (p21, Cip1) 1.3 9.8 8.6 1.0 2.0 2.0 1.0 8.0 7.5
NM_006763.1 BTG family, member 2 (BTG2) 1.5 6.1 6.5 1.1 1.7 2.1 1.4 5.3 3.7
NM_006472.1 upregulated by 1,25-dihydroxyvitamin D-3 (VDUP1) 1.0 3.5 3.5 1.0 1.5 2.6 1.0 2.3 3.0
NM_001924.2 growth arrest and DNA-damage-inducible, alpha 1.4 7.5 7.5 NC 1.9 2.6 1.1 7.0 7.5
BC003637.1 Similar to DNA-damage-inducible transcript 3 1.0 2.6 2.6 1.1 2.1 2.5 NC 2.6 2.8
NM_014454.1 p53 regulated PA26 nuclear protein (PA26) 1.1 4.0 3.0 1.1 1.4 2.6 1.1 3.7 3.7
NM_004701.2 cyclin B2 (CCNB2) -1.1 -8 -13.9 NC 1.3 -1.3 -1 -4.9 -19.7
NM_001255.1 CDC20 (cell division cycle 20) -1.9 -90.5 -147 NC 1.6 -1.9 -1.6 -13 -157
NM_021873.1 cell division cycle 25B (CDC25B) -1.1 -1.6 -2.5 NC NC -1.4 -1 -2.3 -3.25
NM_001827.1 CDC28 protein kinase 2 (CKS2) -1.1 -4.6 -6.5 NC 1.6 -1.6 -1.2 -3.5 -5.7
NM_001168.1 survivin (BIRC5) -1.1 -27.9 -294 NC NC -1.6 NC -6.9 -181
Transcription, translation, oncogenesis, angiogenesis, other          
NM_021953.1 forkhead box M1 (FOXM1) -1.2 -13.9 -42.2 -1.1 -1.2 -2.0 NC -2.8 -45.3
NM_000465.1 BRCA1 associated RING domain 1 (BARD1) -1.3 -1.9 -2.0 NC -1.1 -2.1 -1.2 -2.6 -4.9
NM_003368.1 ubiquitin specific protease 1 (USP1) NC -2.6 -1.6 NC -2.0 -1.4 NC -2.1 -1.9
NM_006716.1 activator of S phase kinase (ASK) -1.2 -6.5 -5.3 -1.2 -1.3 -2.0 -1.1 -4.6 -11.3
NM_003246.1 thrombospondin 1 (THBS1) NC -2.0 -3.5 -1.9 -1.4 -2.6 -1.1 -1.6 -4.6
NM_001147.1 angiopoietin 2 (ANGPT2) 3.5 3.5 8.0 1.7 5.3 8.0 -0.5 4.9 2.8
AF187858.1 angiopoietin-2 isoform-1 NC 2.6 4.3 NC 1.5 3.5 NC 2.0 2.0
NM_000435.1 Notch (Drosophila) homolog 3 (NOTCH3) 1.3 3.0 2.8 1.0 2.3 2.1 NC 2.1 3.0
NM_001674.1 activating transcription factor 3 (ATF3) NC 1.5 2.5 NC 1.7 2.5 NC 2.6 4.3
NM_003158.1 serinethreonine kinase 6 (STK6) -1.7 -11.3 -9.8 1.1 1.2 -1.7 -1.3 -8.6 -26
NM_003600.1 serinethreonine kinase 15 (STK15) -1.2 -3.7 -8.6 NC NC -1.6 -1.3 -4 -6.1
AF162704.1 androgen receptor mRNA NC 1.3 -1.6 1.2 1.3 -2.1 -1.1 -1.6 -2
Resistance to chemotherapeutic agents          
NM_000693.1 aldehyde dehydrogenase 1A3 (ALDH1A3) NC 4.0 3.2 1.0 1.1 2.1 1.2 4.9 4.3
NM_005980.1 S100 calcium-binding protein P (S100P) 1.0 5.7 4.0 1.5 2.6 3.0 NC 2.6 2.6
  1. The genes in this list showed a >2 fold change in expression in at least one time point in both mono and combination treatment.
  2. NC: No change; Negative value: Decrease; Positive value: Increase.